<DOC>
	<DOCNO>NCT01554852</DOCNO>
	<brief_summary>The purpose study compare standard chemotherapy regimen cyclophosphamide , dexamethasone plus thalidomide new regimen cyclophosphamide , dexamethasone plus lenalidomide without carfilzomib . Patients best response initial treatment may also give combination cyclophosphamide , dexamethasone plus bortezomib . Patients relatively fit may , doctor 's advice , go receive intensive chemotherapy , support transplant blood cell . This standard treatment patient may offer anyway even n't take part study . After maximal response achieve treatment described , long myeloma get bad , patient treat either long-term lenalidomide , lenalidomide vorinostat , receive treatment , close observation .</brief_summary>
	<brief_title>Use Thalidomide , Lenalidomide , Carfilzomib , Bortezomib Vorinostat Initial Treatment Newly Diagnosed Multiple Myeloma Patients</brief_title>
	<detailed_description>The last ten year see introduction number effective new anti-myeloma agent clinical arena . These agent show highly effective relapse set introduce treatment earlier disease course . This study aim address randomise set key question concern use thalidomide , bortezomib , lenalidomide , carfilzomib vorinostat initial treatment multiple myeloma patient . Newly diagnose patient age symptomatic myeloma require treatment eligible . For initial treatment , thalidomide combination cyclophosphamide dexamethasone , UK gold standard , compare new combination lenalidomide , cyclophosphamide dexamethasone without carfilzomib . For patient sub-optimal response initial therapy , response proteasome inhibitor bortezomib assess , previous study demonstrate able induce response improve progression-free overall survival patient resistant standard chemotherapy . Patients young fit enough tolerate autologous transplant proceed high dose melphalan peripheral blood stem cell rescue maintenance randomisation . Older less fit patient go directly maintenance randomisation . The value lenalidomide lenalidomide combine vorinostat maintenance assess randomise eligible patient receive either lenalidomide , lenalidomide combine vorinostat maintenance therapy , close observation . The primary end point study overall progression-free survival ( OS PFS ) . Secondary end point include response toxicity . A number laboratory base study also perform order determine patient specific factor predict overall progression-free survival response treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Aged 18 year great Newly diagnose symptomatic multiple myeloma nonsecretory multiple myeloma Provide write informed consent Women childbearing potential male patient whose partner woman child bear potential must prepare use contraception accordance ( consent ) Celgeneapproved process thalidomide lenalidomide Risk Management Pregnancy Prevention , commit absolute continuous abstinence Women child bear potential must negative pregnancy test perform healthcare professional accordance Celgeneapproved process thalidomide lenalidomide Risk Management Pregnancy Prevention Asymptomatic myeloma Solitary plasmacytoma bone . ( Patients previous solitary plasmacytoma progress symptomatic nonsecretory myeloma eligible ) Extramedullary plasmacytoma ( without evidence myeloma ) Previous ( &lt; 5 year since diagnosis ) concurrent active malignancy , except surgicallyremoved basal squamous cell carcinoma skin , treat carcinoma situ breast cervix , incidental histologic find prostate cancer ( TMN stage T1a 1b ) . Patients remote history ( &gt; 5 year ) cure malignancy may enter . Documented diagnosis Myelodysplastic Syndrome ( MDS ) meet International Prognostic Scoring System ( IPSS ) criteria highrisk disease Previous treatment myeloma , except follow : local radiotherapy relieve bone pain spinal cord compression ; prior bisphosphonate treatment ; corticosteroid within last 3 month Known history allergy contributable compound contain boron mannitol Grade 2 great ( NCI criterion ) peripheral neuropathy Acute renal failure ( unresponsive 72 hour rehydration , characterise creatinine &gt; 500Âµmol/L urine output &lt; 400 mL/day requirement dialysis ) Lactating breastfeed Patient active prior hepatitis C Caution advise patient past history ischaemic heart disease , pericardial disease , acute diffuse infiltrative pulmonary disease psychiatric disorder , evidence impair marrow function elevate liver function test , exclusion essentially discretion treat clinician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>myeloma</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>vorinostat</keyword>
	<keyword>Zolinza</keyword>
	<keyword>stem cell</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>Kyprolis</keyword>
</DOC>